P atients affected by type 1 diabetes (T1D) suffer from lack of insulin secretion by the pancreas, due to the autoimmune destruction of the insulinproducing beta cells. This translates into elevated plasma glucose concentration with deleterious effects in the cardiovascular system, leading to serious long-term complications. With the improvement of continuous glucose monitoring (CGM) technology, a significant amount of research has been focused in the last decade on the development of an artificial pancreas (AP), that is, a closed-loop glucose control system that automatically dispenses insulin. The AP is now closer to reality [1] . An AP system was first approved by the U.S. Food and Drug Administration (FDA) in 2016 [2] . The system still requires user intervention at mealtime, as currently done in openloop insulin pump therapy, to administer an insulin bolus based on carbohydrate counting (a hybrid closed-loop system).
A first-generation AP is thus expected to be commercially available soon. However, issues still need to be addressed for the performance improvement of the AP, such as inter-and intrasubject physiological variability, efficient compensation of real-life disturbances (such as exercise, alcohol, and diseases), pump faults, sensor accuracy, and large dynamic lags induced by the subcutaneous administration of insulin. This last challenge constitutes the focus of this article.
Insulin is a glucose-lowering hormone that promotes glucose transport through the cell membrane for its consumption or storage. Glucose regulation is completed in the human body through counterregulatory hormones, such as glucagon that promotes glucose production by the liver, resulting in an increase of blood glucose concentration. However, glucagon secretion by the alpha cells in the pancreas is also affected as the disease progresses along time, increasing the risk of suffering hypoglycemia. Severe hypoglycemia can provoke coma and death.
The unidirectional effect of insulin has major implications in the design of an AP. This effect is aggravated by the significant lag introduced by subcutaneous insulin infusion, which is currently the safest infusion route for a commercial AP, as opposed to the endogenous pancreas that secretes insulin directly into portal circulation (the vessels that connect the pancreas and other organs with the liver, which acts as a first blood filter before entering the main circulatory system). Even in approaches with concomitant infusion of glucagon (the so-called dual-hormone AP), mechanisms are necessary to avoid an excess of insulin delivery that may lead to late hypoglycemia, thereby risking the patient's safety. Regardless of how these mechanisms are incorporated into the control schemes, all of them rely on pharmacokinetic models to predict either circulating plasma insulin or a measure of insulin on board (IOB), such as the insulin depot remaining at the subcutaneous tissue before entering circulation. In this article, methods to constrain insulin delivery are reviewed as well as the subcutaneous insulin pharmacokinetic models and estimatorson which they can rely.
A significant challenge in the prediction of physiological signals such as insulin concentration is the large intrasubject variability that patients suffer. Indeed, in terms of control engineering, a patient is a highly time-varying uncertain plant. The intraday and day-to-day patient's behavior change due to circadian rhythms (24-h rhythmic physiological oscillations driven by the body clock, for instance, daily patterns in insulin sensitivity) and other multiple sources of uncertainty arise in key physiological processes such as meal absorption and subcutaneous insulin absorption. Despite this high variability and uncertainty, the use of population models for the prediction of insulin pharmacokinetics (that is, how the infused insulin appears in blood) is still common practice.
The impact of variability on the model prediction and its implication in closed-loop performance is analyzed. Nevertheless, large intrasubject variability suggests that realtime state and pharmacokinetic parameters estimation is convenient, even when individualized models are considered. The availability of continuous glucose measurements allows for addressing this problem, should an observable glucose-insulin model be available. This article reviews and discusses different proposed observer techniques. See "Summary" for an overview of the entire article.
ThE SubCuTANEOuS INSuLIN ROuTE
The pancreas secretes insulin into the portal vein toward the liver, which acts as a first filter before insulin reaches systemic circulation. In the liver, insulin promotes glucose storage in hepatic cells, decreasing glucose production. In the fat and muscle cells, insulin acts as a key that triggers the mobilization of glucose transporters to the cell membrane, promoting glucose uptake by the cell. Plasma glucose concentration decreases as a result of both actions. The dynamic lag of insulin action is estimated to be approximately 30 min [3] .
An AP is a classic closed-loop glucose control system (see Figure 1 ) that automatically dispenses insulin to a patient (the process), and has three main components: the continuous glucose monitor (the sensor), the insulin infusion pump (the actuator), and the control algorithm (the controller). Contrary to the pancreas, an AP cannot have direct access to the hepatic portal circulation for insulin infusion. Implantable insulin pumps that infuse insulin into the peritoneum (that is, the body cavity containing the Summary n AP is a closed-loop control system designed for automatic insulin delivery in T1d patients who do not produce insulin. The lack of insulin secretion is replaced by exogenous insulin infusion driven by the controller. This exogenous insulin is usually infused beneath the skin, which entails a significant lag bet ween its injection and peak effect. This lag poses an important challenge to glucose control because the controller cannot easily counteract the effect of injecting too much insulin. Thus, methods are needed to limit insulin delivery based on some mea- A abdominal organs) were proposed [4] , in an attempt to closely emulate the pancreas. However, external insulin pumps that infuse insulin through the skin (the so-called subcutaneous route) are the only ones that are currently considered feasible for a commercial AP, due to their minimal invasiveness. External insulin pumps were first introduced in the 1980s and are now a well-established, open-loop insulin therapy [5] . Traditional pumps infuse insulin through a small, flexible tube (a catheter) with a needle allocated into the fat layer under the dermis (the subcutaneous adipose tissue). Patch pumps with no visible catheter are also available [6] .
Insulin pumps use fast-acting insulin analogs (such as insulin aspart [7] or insulin lispro [8] ), which are synthetic insulin molecules with some modification in the amino acid chain (compared to human insulin) to speed up subcutaneous absorption and obtain a faster insulin action. No significant differences in pharmacokinetics and metabolic effects between insulin aspart and lispro are found [9] . Insulin molecules can be in the form of hexamers (groups of six molecules), dimers (groups of two molecules), or monomers (a single molecule). Once infused at the subcutaneous tissue, the generated insulin depot starts diffusing from the infusion site while dissociation of hexamers into dimers and monomers occurs. The molecule structure of insulin analogs is designed to facilitate this dissociation since only dimers and monomers are small enough to go through the capillary wall and thus be absorbed toward circulation [10] . The lag introduced by subcutaneous absorption is estimated to be approximately 50 min [3] .
Subcutaneous insulin pumps are combined with subcutaneous, needle-type, continuous glucose monitors that compute plasma glucose values from electrochemical measurements of interstitial glucose. Dynamics of glucose transport between plasma and the interstitial fluid introduce a measurement lag estimated in approximately 10 min [3] .
The lag induced by the subcutaneous route sums to 90 min, since insulin is infused until its peak effect (50 min for insulin absorption, 30 min for insulin action, and 10 min for glucose measurement). This significant dynamic lag poses an important challenge to glucose control, especially because once insulin is infused, its effect cannot be easily counteracted by the controller, unless the patient eats carbohydrates. Only dual-hormone AP systems can counteract an insulin excess with glucagon infusion at the expense of much higher system complexity. However, glucagon administration must also be limited since its excess may produce side effects, such as nausea and vomiting [11] . Thus, mechanisms are necessary to avoid an excess of insulin delivery due to controller's overactuation because it may lead to late hypoglycemia, thereby risking the patient's safety. These mechanisms constitute a critical component of any AP.
Large intrasubject physiological variability is an additional important challenge for the AP and is responsible, at least in part, for the difficulties of achieving good glycemic control. Currently, patients still have an average exposure to hypoglycemia (< 70 mg/dL) of over 1 h/day and to hyperglycemia (> 180 mg/dL) of higher than 9 h/day [12] . The sources of physiological variability are not fully understood, although variability of subcutaneous insulin absorption [13] , [14] and changes in insulin sensitivity (due to circadian rhythms [15] and premenstrual periods in women [16] ) seem to play a major role. Meal ingestion also has a highly variable effect on glucose homeostasis [17] .
An intrasubject variability of 27% was reported for time-to-peak plasma insulin concentration [parameter tmaxI in model (26)- (28) ] in a pharmacokinetic study of insulin aspart in subjects with T1D [13] . Nearly 40% of this variability was attributed to variations in depth of cannula insertion, insulin site age, and local tissue perfusion. In contrast, insulin clearance was highly reproducible in the same study. A recent study with insulin lispro also showed an important impact of lypohypertrophia (the accumulation of abnormal mass of fat under the skin) of the insulin injection site on insulin absorption and insulin effect [18] . Lypohypertrophia appears when the same injection site is used repeatedly and is characterized by hypertrophic adipocytes, reduced vascularization, and lower capillary density. Although patients are advised to rotate the injection site, a prevalence of lypohypertrophia ranging from 28 to over 64% is reported (depending on the country) as more frequent in T1D [18] . Compared to normal adipose tissue, lypohypertrophia substantially increased intrasubject variability both in pharmacokinetic and pharmacodynamic parameters. The coefficient of variance (CV) of the area-under-the-curve of plasma insulin after an insulin injection in lypohypertrophic adipose tissue ranged from 55 to 65% (compared to 11-20% for normal adipose tissue), corresponding to a three-to five-fold increment. No effect of lypohypertrophia on the time-to-peak plasma insulin was found. Intrasubject variability of the insulin effect (measured as the area-under-the-curve of the exogenous glucose infusion needed to keep plasma glucose constant after insulin injection) was generally higher, especially during the first hour when the CV reached 90% (compared to 66% for normal adipose tissue).
Although the above study was conducted with insulin injections and not an insulin pump, it highlights the challenge that intrasubject variability poses for any insulin therapy with subcutaneous administration, including an AP. Current insulin infusion sets in pumps need to be replaced every two to three days to avoid inflammation and infection. Differences in insulin absorption of consecutive infusion sites due to the development of lypohypertrophia can jeopardize the AP performance, increasing the risk of hypoglycemia. Besides, current systems need two skin punctures, one for the sensor and one for the insulin pump, making the rotation of the infusion site more difficult [19] . (See "Why Is Insulin Estimation and Prediction Needed in an Artificial Pancreas?" for a summary of the key facts described in this section that justify the use of insulin estimators and predictors.
GLuCOSE-INSuLIN MOdELS
Models describing the glucose regulation by insulin (henceforth referred to as glucose-insulin models) are needed for the design of controllers and observers. The reader is referred to [20] and [21] for a historical perspective on modeling the glucose-insulin system, including models to measure key physiological signals or parameters in glucose metabolism (the so-called minimal models), fine-grained models that provide a detailed description of the physiological processes for simulation purposes (maximal models), and models for control with a simpler structure capturing the most relevant dynamics. Independent of the model complexity, the description of glucose metabolism in the context of any subcutaneous insulin therapy such as the AP implies the following model components (see Figure 2) : » A subcutaneous insulin pharmacokinetic model describing how insulin appears in blood after subcutaneous infusion. Although modeling of subcutaneous insulin pharmacokinetics dates back to the 1980s, only works related to the fast-insulin analogs currently used in insulin pump therapy are relevant here (insulin lispro and aspart) as well as new insulin formulations under investigation for ultrafast insulin absorption. 
Why Is Insulin Estimation and Prediction
Needed in an Artificial Pancreas?
T o keep glucose levels of patients affected by T1d in a safe range, the AP can be used as a closed-loop control system that automatically dispenses insulin. However, the use of insulin as control action has different limitations:
• Insulin has a unidirectional effect lowering glucose values.
Any insulin excess cannot be compensated beyond pump switch off, and external actions are required, such as meal consumption or glucagon administration.
• Insulin is delivered subcutaneously, as opposed to the pancreas, which delivers insulin into blood. This can be addressed with the design of insulin observers.
» An insulin action model describing how plasma insulin concentration exerts its effect on glucose metabolism. This component mainly involves the transport lags from plasma to the insulin action site. » A carbohydrate digestion and absorption model describing how glucose enters blood after a meal. This model has proven to be challenging due to the complex physiology of gastric emptying and intestinal absorption and the lack of glucose absorption rate measurements, unless complex clinical studies are conducted. » A glucose metabolism model describing the comprehensive effect of insulin and meals on plasma glucose concentration. More complex models may also include other effects like glucagon and exercise. Three widely used models in the AP community, from lower to higher complexity, are the Bergman model (minimal) [22] , Hovorka model (intermediate complexity) [23] , and Dalla Man model (maximal) [24] . The latter is the core of the UVA-Padova T1D simulator [25] , a simulation tool for the evaluation of glucose controllers accepted by the FDA as a substitute for animal trials. Since models for simulation are not in the scope of this article, it will not be presented here. Table 1 ) is a seventhorder, nonlinear model that includes all model components in Figure 2 . Carbohydrate digestion and absorption is described by the impulse response of a second-order linear model, with input DG the amount of carbohydrates in the meal and output of the glucose rate of appearance in blood, ( 
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The impulse response for an insulin bolus
This model is often referred to as a biexponential model [29] , [30] . An alternative state-space representation of (1) is the compartmental model
where ( ) q t 1 is the mass of insulin at the subcutaneous tissue, ( ) q t 2 is the plasma insulin mass, and VI is the insulin volume of distribution, which is the ratio between the insulin clearance ( ) Kcl and insulin elimination rate constant ( / ).
It becomes apparent from (3)- (5) that the biexponential model corresponds to the Hovorka subcutaneous insulin pharmacokinetic model, with the subcutaneous space simplified to a single compartment and the parameter equivalences t 1 max Figure 3 shows a comparison of the response of both models to an insulin bolus of 1 U, considering published nominal parameters.
INSuLIN ObSERvERS
Independent of the control algorithm used in an AP, either single-hormone (only insulin) or dual-hormone (insulin and glucagon) mechanisms are necessary to avoid an excess of insulin delivery for safety reasons. These mechanisms must rely on subcutaneous insulin pharmacokinetic , min k 0 138
body weight 70 kg; biexponential:
, min 55
models (as the ones described in the previous section) for the estimation of either circulating plasma insulin or IOB. IOB represents the injected but still unused insulin that will have an effect in the future. Nevertheless, even with the use of individualized models, the real-time estimation of those signals is convenient for effective closed-loop glucose control because large intrasubject variability can compromise performance (see "Models and Variability" for details). This problem could be addressed with the design of insulin observers, in case an observable glucose-insulin model is available. See "Observability of Nonlinear Systems" for a description of observability tests applicable to glucose-insulin models in Table 1 . An observer is a realtime estimator with a feedback mechanism for recursively correcting its estimated state based on the actual outputs measured from the real physical system. Observers can also be used for the real-time estimation of model parameters via a state extension. The Luenberger observer and different extensions of the Kalman filter to nonlinear systems (see "Kalman Filter Extensions to Nonlinear Systems") are proposed in the literature. Basic knowledge of the Luenberger observer and linear Kalman filter is assumed. Depending on the modeling framework, the term "observer" (deterministic) or "filter" (stochastic) is used. For instance, the Luenberger observer strictly applies to deterministic systems, whereas the Kalman filter is formulated in a stochastic framework that incorporates models for measurement and system noise, and it produces an explicit estimate for the covariance of the system state.
Observers are integrated into some AP systems for several purposes. In [31] , a Kalman filter is used in a model predictive control (MPC)-based system to update two model parameters: 1) a glucose flux quantifying model mismatch and 2) carbohydrate bioavailability. A stochasticbased approach incorporating competing models differing in the rate of subcutaneous insulin absorption and action, as well as carbohydrate absorption, are used to account for intrasubject variability. In [32] , a Luenberger observer is used to estimate the initial state of the prediction model in a zone MPC system [33] . In [34] , its performance is compared to a moving horizon state estimator (MHSE), which is based on a constraint optimization problem that calculates the optimal sequence of the process and the measurement noises to minimize a cost function within a fixed history horizon. It is shown to have a better performance than the Luenberger observer in simulation, rejecting a meal disturbance quicker without inducing hypoglycemia.
Despite the risk to the patient's safety from plasma insulin or IOB estimation errors due to large intrasubject variability, the literature addressing the design of insulin observers and, most importantly, assessing its performance with clinical data, is scarce.
The Hovorka glucose-insulin model [23] and the extended Kalman filter (EKF) are used in [35] , where real-time estimation of plasma insulin concentration from CGM measurements in subjects with T1D is addressed in the context of insulin observers for closed-loop control. The extra equation
where ( ) t IG represents interstitial glucose (what the CGM measures) and x is the time constant for plasma-to-interstitial space glucose transport, is added to the Hovorka model to describe the lagged measurement by the CGM. Process and observation noises are also added. In addition, state observers are designed to estimate uncertain pharmacokinetic parameters, in particular the fractional elimination rate, , ke and time-to-maximum insulin absorption, tmaxI (see Table 1 ), by building new extended models in which these parameters are considered as new states with no dynamics. The observability of these models is demonstrated analytically through Lie derivatives.
Plasma insulin estimations are validated first in a simulation study, with a total of five meals and 25-h duration. A clinical validation was then conducted, using real data from 12 patients with T1D who underwent four mixed meal studies during 5 h, after a glucose normalization phase [36] . Fig ure 4 shows an illustrative example of the observer performance against clinical data for a sample patient. As a compar ator, the use of a population model for insulin prediction is considered as a comparator, since it is still a common practice despite the expected variability in insulin pharmacokinetics (see the section "The Subcutaneous Insulin Route"). With regard to variability, different scenarios are devised: natural physiological variability in insulin pharmacokinetics at a given infusion site along the lifetime of the infusion set and more abrupt changes in insulin pharmacokinetics due to the use of a new infusion site after rotation, with different subcutaneous tissue properties (for instance, affected by lypohypertrophia [18] ). Due to the limited duration of the data (5 h), the above scenarios are characterized in [35] through the observer initialization, since a change in infusion site is expected to imply a larger mismatch between the observer model and the actual behavior. Thus, three cases are The interconnection of monotone systems may be studied by considering a flow ( ) ( , ).
where ≤ is a given relation order [S4], as represented in Figure S1 .
From an analytical point of view (see [S4] ), the rate of change of the state vector ( , , )
of a monotone system can be described as
where the vector function ( , , ) f f fn
For cooperative systems [S7], the relation order is induced by the corresponding positive orthant, which is characterized by a metzler Jacobian matrix, that is,
monotonicity can also be characterized by a species graph, in which a node is assigned to each state, parameter, input, and output, and a spin assignment is conducted for each node based on the sign of partial derivatives (see [S5] ). moreover, the monotonicity of the system with respect to the parameters of the model can be analyzed by considering the parameters as system states in an extended model [S8].
fiGuRe s1
The relation order in the flow of a monotone system.
parameters. Figure 4 shows how real-time estimation of pharmacokinetic parameters leads to the detection of significant deviations in plasma insulin prediction with the population model, reaching more accurate estimations after a transient time (the solid blue line). The impact of this transient time on closed-loop performance needs to be investiga ted. Once adapted, insulin estimation is expected to remain accurate enough (the solid green line). The root mean square error (RMSE) and mean absolute relative deviation (MARD) are computed for the assessment of the observer performance in the cohort of patients. The obtained RMSE values are 24.5 ± 16.5 mU/L for case 1), 14.9 ± 7.7 mU/L for case 2), and 6.6 ± 3.9 mU/L for case 3). Consideration of the pharmacokinetic parameters ke and t I max as extended states significantly improves estimation accuracy, with a reduction of RMSE of 73%, with respect to a population model approach.
In the simulation study presented in [37] , the unscented Kalman filter (UKF) is used to calculate the bolus insulin size based on a state estimate (which includes plasma insulin) and the meal size announced by the patient. The rationale is that aside from the meal size announcement, information provided by the early postprandial period can help to reduce the impact of errors in carbohydrate counting by the patient, allowing for the computation of more accurate insulin bolus doses even at the expense of a delayed administration. The IVP glucose-insulin model [28] described in the section "Glucose-Insulin Models" and Table 1 is used in this work. Insulin sensitivity and the meal compartment are also estimated via a 
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No specific results on the observer performance are reported. They conclude that administering the meal bolus 15 min after mealtime both reduces the risk of hypoglycemia when meal size is overestimated by 50% and the time spent in hyperglycemia for a meal size underestimation by 50%. However, administration of insulin at mealtime is optimal when the meal size is exactly known. Due to the problem posed in this work, administration before the meal is not considered. However, clinical trials that assessed the best timing for meal bolus times generally conclude that the administration of the insulin bolus between 10 and 20 min before the meal leads to reduced glycemic excursions, as compared to mealtime or after the meal [38] , [39] .
Other works address the design of insulin observers, but either an intravenous route is considered, not used in current AP systems, or endogenous insulin secretion is included, which does not apply to T1D. These works are reviewed below, 
Lie Derivatives
The lie derivative of ( ) h x with respect to
and is calculated recursively as follows:
The system (S5)-(S6) is considered observable if the following Jacobian matrix
has rank , n where n is the system order.
Empirical Observability Gramian
The gramian observability matrix W0 is also determined for observability analysis. This matrix quantifies generalized energy transfer E0 from initial state x0 to the output within an infinite time horizon
The gramian observability matrix can be computed from experimental or simulation data within a region where the process is to be operated (see [43] It is worth noting that even when the system is observable, difficulties in the reliable estimation of pharmacokinetic parameters may arise due to nonidentifiability issues. The a priori or structural identifiability property of a model indicates if the parameters of the model can be determined, assuming that all observable variables are error free. The lack of structural identifiability arises due to the model structure only and is independent of the amount and quality of the given experimental data. However, a parameter that is structurally identifiable may still be practically nonidentifiable. This can arise due to insufficient amounts and quality of experimental data or the chosen measurement time points. common problems in the identification of glucose-insulin models are the lack of excitability of basal insulin, which is rarely variable enough, especially during the night, and the administration of insulin boluses at mealtime, making it difficult to separate the meal and insulin effects on glucose after meal intake.
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where y R r ! are the measurements and the random variables ( ) w k and ( ) k v represent the process and measurement noise, which are assumed to be independent, white, and with normal probability distributions of variances Q and , R respectively.
The kalman filter provides an efficient computational method to estimate the state of a process in a way that minimizes the mean of the squared error in a two-step process: the prediction step (the current state estimate is projected ahead in time) and the correction step (the projected estimate is adjusted by an actual measurement).
Since the time of its introduction, the kalman filter has been the subject of extensive research and application. The kalman filter theory has been extended to nonlinear processes, given by In addition, the derivation of the Jacobian matrices are nontrivial in most applications and often lead to significant implementation difficulties. These disadvantages may be overcome with the use of the UkF. The UkF is based on the UT, which is a deterministic sampling approach to capture mean and covariance estimates with a minimal set of n 2 1 + state sample points, called sigma points, based on a square-root decomposition of the prior covariance. These sigma points are propagated through the nonlinearity, without approximation, and a weighted mean and covariance is found.
The sigma points are chosen so that their sample mean and sample covariance are in agreement with the mean x r and covariance P of the n-dimensional random variable .
x The underlying idea is to approximate the probability distribution instead of the function (see Figure S3) . moreover, kalman filter extensions can also be used in continuous-time systems that are represented by differential equations
( ) ( ( ), ( )) (), ( )~( , ( )), x t f x t u t w t w t N Q t
after a discretization procedure. The glucose-insulin models found in the literature belong to these kinds of systems.
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since they address glucose-insulin models and may be relevant to future developments in the AP context. A reduced-order Luenberger observer [40] is designed in [41] for the three-state minimal Bergman model [22] , where endogenous insulin secretion in the original model is substituted with an intravenous insulin infusion to represent subjects with T1D. Disturbances are included in the form of an exogenous glucose infusion rate. The observer aims to reconstruct the remote insulin compartment and plasma insulin deviation from plasma glucose deviation measurements. The obtained results are tested on nonlinear, closed-loop simulations using the disturbance rejection linear-quadratic method. A standard meal disturbance with a 6-h duration is considered as the test case. It is shown that the observer is faster than the system itself and can provide very good state recovery performance.
In [42] , the Bergman model is used in combination with different filters (symmetric UKF, EKF, simplex UKF, and particle filter) for the estimation of plasma insulin concentration. Endogenous insulin secretion is considered. Furthermore, linear interpolation is used to obtain glucose measurements in a time grid of 1 min. After evaluating observability by the Lie derivatives, the designed observers are validated with data from an IVGTT (see the section "Glucose-Insulin Models") in nondiabetic subjects by computing the RMSE. The symmetric UKF showed better results with an RMSE value of 10.277 mU/L, followed by EKF with 13.533 mU/L. This work is extended later in [43] to incorporate parameter estimation via state extensions characterizing first-and second-phase insulin responses as well as compartments for glucose and subcutaneous insulin inputs and subcutaneous glucose measurements. Both the observability of states and external inputs and the identifiability of model parameters are analyzed by the empirical observability Gramian from data. For the purpose of model validation, four scenarios are simulated: an IVGTT for nondiabetic subjects, an oral glucose tolerant test (OGTT) for nondiabetic subjects, an IVGTT for diabetic subjects, and an IVGTT with an insulin bolus after 30 min for diabetic subjects. Similar to IVGTT, the OGTT is a clinical test to analyze glucose metabolism. However, glucose is administered orally instead of intravenously. Simulated scenarios are compared with measured data from nondiabetic and diabetic pigs. These data are used for parameter identification and model adaptation. The results are graphically evaluated, concluding that a real-time estimation of states such as plasma insulin, and parameters such as secondphase insulin response gain, is possible. It may improve realtime state prediction and the personalized model.
In [44] , the Bergman model is used with the UKF, the cubature quadrature Kalman filter (CQKF), and the Gauss-Hermite filter (GHF) to track plasma glucose, plasma insulin, and interstitial insulin levels. The model is based on the work presented in [42] . Thus, endogenous insulin secretion is again considered. The above filters are compared based on estimation accuracy, in terms of RMSE, and computation efficiency by simulation. Results show that all three filters successfully trace glucose and insulin levels from noisy blood glucose measurements with similar performances (the RMSE plots overlap), but the UFK computational load is lower.
In [45] - [47] , nonlinear, discrete-delay, differential equation (DDE) models are used in the context of closed-loop glucose control. The authors state that DDE models better represent the pancreatic insulin delivery rate, allowing for the extension of the methodologies to type 2 diabetes. Moreover, the model has satisfactory properties, such as positivity and boundedness of solutions or local attractivity of a single positive equilibrium. The model is also statistically robust since its parameters are identifiable with very good precision by means of standard perturbation experiments, such as IVGTT. The authors consider the problem of tracking a desired plasma glucose trajectory from initial hyperglycemia, making use of only glucose measurements. To this aim, they use the nonlinear observer for time-delay systems to estimate the plasma insulin concentration 
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where ( ) G t t and ( ) I t t denote the glucose and insulin estimates, respectively, and Q 1 -is the inverse matrix of the function
( , )
.
The observer gain matrix W R 2 1 ! # is designed to ensure that
is Hurwitz with prescribed eigenvalues in the left half of the complex plane. Numerical results from simulations show that this approach is robust with respect to the uncertainties of the model parameters as well as the glucose measurement errors and insulin pump malfunctions. Table 2 summarizes the above results.
INSuLIN INfuSION LIMITATION IN ThE ARTIfICIAL PANCREAS
As previously stated, the main justification for the prediction (or estimation from data) of plasma insulin or IOB in an AP is the avoidance of the controller's overactuation (for instance, after a meal disturbance), inducing an excessive insulin infusion with the consequent risk of hypoglycemia. MPC, proportional-integral-derivative (PID), and fuzzy logic (FL) are the major control strategies used in the AP framework and most extensively evaluated through clinical trials [48] . According to [49] , 18 AP systems are currently under development at different stages, of which eight are based on MPC, six on a PID-type control algorithm, three on FL, and one in a bio-inspired approach. All control strategies must deal with the limitation of insulin infusion for the sake of safety.
Model Predictive Control
One of the advantages of MPC is that it can easily incorporate constraints into the optimization process of the defined cost function. An example of such a procedure is given in [50] , where a dynamic safety constraint on the maximum rate of insulin delivery based on empirical clinical knowledge is integrated into an MPC scheme, to avoid overdelivery of insulin. The following constrained cost function is considered , min y y u u u u
where y R is the vector of future calculated deviations of the insulin infusion rate with respect to the basal rate uss t (that is, the insulin rate required at steady state to obtain the desired steady-state glycemia), with m the control horizon; and u R m 1 ! D # is the vector of future insulin infusion increments. The constraint, expressed in terms of deviations of the insulin infusion rate with respect to the basal rate , uss t indicates that the insulin infusion rate is limited between half its basal value and a time-dependent maximum deviation from its basal value
where
is the insulin needed at time k to compensate a meal, ( ) M k is the amount of carbohydrates from the meal absorbed at time , k and IC [U/g] is the insulin-tocarbohydrate ratio used currently by clinicians (that is, how much insulin per gram of carbohydrate must be administered to compensate a meal). Moreover, ( ) I k G represents the insulin needed to compensate for a deviation from the target (considered here to be the steady-state glucose concentration) ( ), G k ss as given by the correction factor ( / ) . CF U mg dL 1 -
6
@ CF is used by clinicians in current insulin therapy to determine how much insulin must be administered to compensate for an excess of one glucose concentration unit with respect to the glucose target. Finally, IOB(k) is the predicted IOB at time , k which is obtained from the convolution of the insulin administered in the last 8 h and a family of "active insulin curves," as given by insulin pump manufacturers ranging in different durations of insulin action from 2 to 8 h. These curves are based on insulin action plots and express the percentage of remaining active insulin along time. Curvilinear and linear versions are available, depending on the manufacturer [51] . Although linear versions are easier to use by patients, curvilinear versions represent better subcutaneous insulin pharmacokinetics and are preferred. The use of dynamic curves to account for daily variations in insulin sensitivity is proposed in [52] . In a simulation study reproducing a 24-h clinical protocol with three meals [50] , limitations of IOB according to (9)-(10) resulted in a reduction of the number of simulations yielding a hypoglycemic event, compared to the same MPC controller without the IOB constraint, from 50% (18.6% of the overall simulation time) to 10% (0.75% of the overall simulation time). This was achieved at the expense of mild hyperglycemia but for very short periods (3.5% of overall simulation time).
In [53] , the insulin limitation problem is cast into an augmented single-input, multiple-output MPC formulation, where the linear combination
of plasma insulin ( ) I t and a measure of the pending effect of IOB ( ) t q are added as new system output. A generalized predictive control (GPC) with extended output ( )
(where ( ) G t is plasma glucose) is then formulated. GPC optimizes the multistage quadratic cost function, which, after signals discretization, is written as
where the first term penalizes the error with respect to the setpoint r along the prediction horizon [ , ] , N N d m and the second term penalizes the control action along the control horizon with bound . Nu Parameters k d and k m are weights. In this case, the following biexponential insulin pharmacokinetic model is used:
which corresponds to (2) with /( ( )), 
Factors sIp and sq in (14) scale the corresponding units of ( ) I t [U/dL] and ( ) t q [Umin/dL] into [mg/dL] for an homogeneous cost index. It is noted that ( ) t q is an area-under-the-curve of plasma insulin concentration, not the mass of insulin.
Finally, another relevant MPC-based AP system is presented in [23] , which was already tested in free living conditions without supervision over three months [54] . The system includes the following safety checks to avoid excess of insulin delivery [31] : 1) insulin infusion rate is limited to two to five times the preprogrammed basal rate, depending on the current glucose measurement, the time since the previous meal(s), and carbohydrate content of meal(s); 2) shutting off insulin delivery when the glucose measurement is below 77 mg/dL; 3) reducing insulin delivery when glucose is decreasing rapidly; and 4) capping the insulin infusion to the preprogrammed basal rate if a pump occlusion is inferred by the MPC. Unfortunately, no more technical details were published other than the ones presented here, to the best of our knowledge.
PID Control
Two approaches with clinical validation are found for insulin limitation in PID-based AP systems: insulin feedback (IFB) and sliding mode reference conditioning (SMRC). Although applied to PID control, these approaches may be used with other control structures.
Insulin Feedback
In a healthy person, the beta cells automatically avoid insulin excess by autoinhibiting the endogenous insulin production, depending on the insulin plasmatic concentration. In T1D this phenomenon is lost, due to the destruction of the autoregulating beta cells. However, an AP can emulate this process using the IFB algorithm [55] , where a prediction of plasma insulin is fed on the forward delivery of insulin of the PID algorithm. All PID-based studies have used this strategy since then [48] , with one exception that is reviewed in the next section [56] .
The classic PID control within the AP framework usually includes the following equation:
where ubasal is the basal insulin needed by the patient to maintain a proper glycemia level between meals and at night (basal metabolic conditions), uPID is the additional control action (insulin delivered) proposed by the PID algorithm to deal mainly with disturbances, and ub lus q is the extra insulin dose needed at meal time (considering meal announcement, where the patient informs the control algorithm about the meal time and estimated amount of carbohydrates).
A possible implementation of the IFB algorithm (see [30] or [29] ) is
where the original control action uAP is limited by an action proportional to the predicted plasma insulin concentration . I For this purpose, the biexponential model (2) is used, with the transfer function given by 
which corresponds to (1) with input signal . uIFB The c parameter multiplying I must be set by the control engineer. The IFB approach described is, from a classical control point of view, mathematically equivalent to a cascade control system [30] , as shown in Figure 5 . For IFB to maintain the original insulin infusion uAP at steady state, the original PID parameters must be retuned, or a reduction in insulin infusion would lead to an increase in glucose concentration [30] . To avoid this, the term uAP in (19) must be multiplied by
h which is equivalent to retuning the controller's proportional gain. Integral and derivative terms may also require some adjustments, depending on the tuning of . The equation
presents an equivalent IFB implementation as a limiting action proportional to , I IB -where IB is the predicted basal plasma insulin In this case, the additional term is zero in basal (stationary) conditions and PID gain retuning is not necessary.
Different studies show the good performance of the IFB approach. In [30] , simulation results using the Hovorka model [23] are presented for 24 h with three meals and a decrement of the peak postprandial excursion. At the same time, a reduction of late-postprandial hypoglycemia is reported. In [55] , the ability of IFB to improve the breakfast meal profile in a 30-h closed-loop, in-clinic study with eight adult subjects with T1D was assessed with a substantial improvement over prior studies, but supplemental carbohydrates after breakfast were needed for three subjects. The clinical study also showed feasibility of overnight control. On the other hand, in [57] , four subjects were studied for 24 h and the IFB, as compared to a standard PID control, reduced the occurrence of hypoglycemia without increasing meal-related glucose excursions. Finally, [58] presents simulation results of the IFB strategy used in a fully implantable AP using intraperitoneal insulin delivery and glucose sensing (that is, the peritoneal cavity, which is the area in the body that contains the abdominal organs, is used for rapid sensing and actuation, better emulating the healthy pancreatic activity). In this case, the IFB alone was not enough to attenuate postprandial undershoot but in combination with antiwindup provided very good results.
Sliding mode Reference conditioning control
SMRC is proposed in [56] to build an external feedback loop called the safety auxiliary feedback element (SAFE), to keep IOB (represented by the size of the subcutaneous insulin depot) inside predefined limits. This measure differs from the active insulin curves currently used in insulin pumps that include insulin pharmacodynamics [59] . Upper and lower limits for IOB can be defined if desired. SMRC uses the modulation of glucose targets as a new degree of freedom for glucose regulation (see Figure 6) . A prediction of IOB, IOB(t), drives a switching function ( ), t SM v triggering a discontinuous signal ( ) t that, after a filtering step, sums to the standard glucose target. The rationale behind SMRC is that it provides an upper limit of IOB by increasing the desired glucose target. Any controller will react in the sought direction of diminishing insulin infusion. The opposite applies when a lower limit for IOB is desired.
SMRC originates on concepts of invariance control and sliding regimes as a transitional mode of operation. In contrast to conventional sliding mode control, the aim here is not evolving toward the equilibrium point. Only when the system (by itself) reaches a given sliding surface separating the space into feasible and unfeasible regions (in this case, characterized by the constraint on IOB) is the sliding regime stabilized by conditioning the reference until the system returns (by itself again) to the feasible region. In this sense, there is no reaching mode because no control effort is done to drive the system to the sliding surface [60] .
Given a (possibly time-varying) upper limit on IOB ( ) t IOB h and system state , ( ) x t the set
is invariant (that is, if the initial state fulfills the constraint ( ) ( ), t t IOB IOB # then it will be fulfilled for all t 0 2 ) for a discontinuous signal ( ) t of the form
with 0 2 + large enough (see [56] for technical details) and where l is the relative degree between the output ( ) t IOB and the input ( ), t superscript ( ) i denotes the i th derivative, and i
x are constant gains. The first-order filter
keeps all signals in the control loop smooth, where ( ) G t RF is the modulated (conditioned) glucose target fed to the controller, ( ) G t R is the standard glucose target (usually constant), and a defines the filter cut-off frequency. Stability of the system is guaranteed, since the SMRC loop acts only on the setpoint, which is always bounded.
Relative degree l is determined by the relative degree of the filter (25) and the relative degree of the IOB predictor, since the controller has a proportional action. Although the subcutaneous insulin pharmacokinetic model in [61] was considered in the initial work [56] (which is the model in the UVA/Padova simulator), the Hovorka subcutaneous insulin pharmacokinetic model [23] was finally chosen in the implementation for clinical evaluation due to parsimony criteria, that is,
( ) ( ( ) ()) . dt dS t t S t S t 1
IOB was then defined as Figure 7 shows the typical time profile of IOB as defined by (26)- (28), expressed as a percentage of the bolus size, yielding a curvilinear subcutaneous insulin pharmacokinetics, also characteristic of active insulin curves provided by insulin pump manufacturers [51] .
Equations (26)- (28) have a relative degree of one, giving rise to a total relative degree of . l 2 = The switching function (24) is
For an interpretation of the above switching function, consider, for simplicity, a constant upper IOB limit . IOB This is used, for instance, in a postprandial period or during the night. The switching function
exceeds the limit , IOB that is, when the predicted IOB is about to violate the constraint. How close IOB is allowed to approach (from below) its limit will depend on the IOB trend, weighted by the tuning parameter . This defines a threshold on IOB, which corresponds to
A rapidly changing IOB will lower this threshold, compared to an IOB slowly approaching the limit. A similar interpretation holds for the variable upper-IOB limit, ( ), t IOB but in this case, the threshold on IOB depends on the difference in the trends for IOB and its limit. When IOB goes beyond this threshold, an increment of the glucose setpoint is triggered, provoked by the discontinuous signal ( ) t and amounting to , + after a transient given by the filter (25) . As a reaction to the new (generally much higher) (26)- (28) ( ) . min t 55 max = I glucose setpoint, the controller will reduce the insulin delivery, impeding the violation of the IOB limit for high enough . + The glucose setpoint will return to its original value after the transient imposed by the filter, when IOB returns below the threshold, in which case ( ) . t 0 = Similar formulas are obtained for lower-limiting IOB, changing the inequality in (23) and the sign for ( ) t (glucose target must be decreased).
SMRC was evaluated, in combination with a PID controller, in an in-clinic clinical study where 20 patients with T1D underwent a standardized 60 g-carbohydrate mixed meal on four occasions (two in open loop and two in closed loop). SMRC showed an improvement of postprandial control, with a significant decrement of postprandial peak and increment of time-in-range (70-180 mg/dL) without a clinically meaningful increased risk of hypoglycemia [62] . Simulation validation of SMRC in combination with other controllers can be found in [63] , demonstrating the benefit of the SAFE loop.
Fuzzy Logic
The two control strategies presented previously (MPC and PID) are based on the use of mathematical models of glucose-insulin dynamics. However, the biological system to be controlled is nonlinear, complex, and subject to lags and uncertainties. Therefore, it is very difficult to capture the physiological behavior of a patient. FL allows the development of a fuzzy controller without any patient model by including fuzzy rules (IF input is A THEN output is B), where A and B are linguistic variables. In this way, a controller can be built from medical expertise [64] . In addition, multiple inputs and multiple outputs can be included in a natural way. Different groups have proposed a fuzzy-controller-based AP [65] , [66] , and insulin limitation based on predictions of IOB are also applied in FL systems.
The MD-logic system presented in [65] is based on 1) a control-to-range layer consisting of fuzzy rules, giving rise to an insulin recommendation expressed as percentage of patient's basal insulin; and 2) a control-to-target layer that takes into account, among other things, special glucose dynamics requiring specific corrections and safety measures. The control-to-range layer considers four inputs: past and future glucose trend and current and future glucose level. The latter is predicted through an autoregressive model. The values of the trend input variables are defined as steep descent, descent, stable, ascent, and steep ascent, defined over the range of ±5 mg/dL/min. Glucose level values are defined as very low, low, normal, normal high, high, and very high, defined over the physiological range for glucose. Two output variables are considered: percent change in patient's standard basal rate and standard bolus. In the control-to-target layer, the final insulin rate to be delivered is computed. A prediction of IOB based on the following piecewise functional approximation of insulin aspart pharmacokinetics is considered [7] : 
and subtracted from the insulin to be delivered (see supplemental data in [65] ). Unfortunately, no further technical details are provided. Another FL approach is the dose safety system presented in [66] and [67] . The fuzzy controller has two components: 1) the FL dosing component, which computes via a rule matrix an insulin dose based on the glucose value, rate, and acceleration, to keep glucose in the range of 80-120 mg/dL; and 2) the dosing personalization component, which computes a personalization scale factor for the computed insulin dose. In [66] , it is stated that the system does not track IOB, although the function will be included in subsequent versions. In [67] , an extension of the system with a hypoglycemia prevention module is presented, which incorporates a hypoglycemia predictor based on pattern-matching techniques from glucose and IOB signals. However, to the best of our knowledge, no further technical details have been disclosed.
OPEN ChALLENGES
The use of the AP in free living conditions poses extra challenges to the performance of the controller and, with it, the efficiency of its mechanisms for insulin infusion limitation. An example is physical activity, which has very different effects on plasma glucose concentration, depending on its type and intensity. Mild and moderate-intensity physical activity requires a reduction of insulin infusion, while more intense activities necessitate a rise in insulin, at least in early recovery [68] . This can affect algorithms limiting insulin infusion under physical activity scenarios, which may need different tuning. However, it implies that the system must be informed in some way about physical activity, such as patient's announcement or measurements from a physical activity monitor.
Moreover, the dynamic lags imposed by the subcutaneous route might be a barrier for efficient compensation of physical activity, which may provoke rapid fluctuations in glucose. Subcutaneous insulin pharmacokinetics can also be affected by physical activity. In [69] , an increase of circulating insulin is observed after a pump basal insulin rate reduction before a moderate-intensity aerobic exercise, which is hypothesized to be due to the increased cardiac output and subcutaneous blood flow during exercise, provoking an acceleration of insulin pharmacokinetics. It is thus expected that physical activity may affect the performance of insulin observers. To date, there are no accurate exercise models. Physical activity can also compromise the accuracy of continuous glucose measurements, with an overall overestimation of glucose values [70] . Possible sources of this loss of performance are changes in subcutaneous blood circulation and increases in body and skin temperature during physical activity, which affect the dynamics of glucose transport between plasma and the interstitial space where the sensor is located.
Another important challenge is postprandial control. There is growing evidence that insulin-dosing algorithms should consider not only the carbohydrate content of a meal but also fat and protein [71] - [73] . An AP study investigating the performance of a low-fat versus high-fat dinner with identical carbohydrate content showed elevated plasma glucose levels during the high-fat dinner, despite the administration of 42% more insulin [74] . Model fitting from data produced in this study revealed not only the expected lag in gastric emptying due to an increased fat content but also a lower insulin sensitivity in the high-fat meal [72] . In [73] , a controlled study was conducted comparing a low, fat-low-protein meal with a high-fat, high-protein meal with identical carbohydrate content, covered with identical insulin doses, showing a twofold glucose incremental area under the curve in the latter case. In the same study, an adaptive, model-predictive, insulin bolus strategy required 65% more insulin, with a 30/70% split over 2.4 h, to achieve the glucose target in the high-fat, high-protein case, compared to low fat, low protein. Further investigation is needed to understand how these findings affect the performance of insulin limitation algorithms in an AP. Meal composition announcement is not desirable, due to the extra burden for patients. Besides, current meal models only consider carbohydrates, which is an important limitation.
The need to incorporate psychological stress into the AP is also under investigation. In [75] , a significant relationship between daily stress (rated by the patient in a fivepoint scale) and glucose variability was found as well as an increased percentage of time in hypoglycemia and reduced carbohydrate consumption. However, mean glucose was not affected. More studies are needed to reveal the clinical significance of these findings and justify its consideration in an AP for individuals more reactive to stress.
As more data is available from long-term, clinical, closedloop studies in free living conditions, improvements addressing all of these aspects may be expected.
CONCLuSION
Glucose control in T1D is a complex problem from the control engineering point of view. The plant (that is, the patient) is a highly variant, nonlinear system due to the nature of physiology and its intrinsic variability. Significant lags are introduced by the use of the subcutaneous route, due to its minimal invasiveness. The fact that insulin has a unidirectional action poses additional challenges to the efficacy and safety of control algorithms. These aspects were introduced in this article, focusing both on physiological knowledge for a thorough understanding of the problem at hand and different control engineering approaches proposed in the AP field to address these challenges.
It becomes apparent that a critical component of any AP is the limitation of insulin delivery based on some measure of insulin in the body. Plasma insulin concentration, active insulin curves, and the size of the subcutaneous insulin depot are examples of such measures. Methods for insulin limitation differ depending on the control framework. MPC incorporates such measures as constraints or in the cost index for optimization. PID control makes use of additional structures such as cascade control or reference conditioning. FL incorporates insulin measures as components of the rule base. All these approaches are based on insulin predictors (or estimators). Due to the large variability, another critical component of an AP is the real-time estimation and adaptation of model parameters. The availability of continuous glucose measurements addresses this problem through the design of observers. Different observer techniques have been used for this purpose, although validation with clinical data is scarce. Results published on the development of insulin observers were reviewed. Some open challenges were also noted. This article aims to introduce the challenge of automatic subcutaneous insulin delivery and the opportunities that it brings to control engineering, to alleviate the current burden of self-control for patients with T1D.
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